These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 35711448)

  • 21. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Sughayer MA; Souan L; Abu Alhowr MM; Al Rimawi D; Siag M; Albadr S; Owdeh M; Al Atrash T
    Vaccine; 2022 May; 40(20):2841-2847. PubMed ID: 35397946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine.
    Basile K; Rockett RJ; McPhie K; Fennell M; Johnson-Mackinnon J; Agius JE; Fong W; Rahman H; Ko D; Donavan L; Hueston L; Lam C; Arnott A; Chen SC; Maddocks S; O'Sullivan MV; Dwyer DE; Sintchenko V; Kok J
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immediate Adverse Reaction and SARS-CoV-2 Anti-Spike Receptor Binding Domain IgG of COVID-19 Vaccines Among Health Staffs.
    Rasheed WS; Sarkees AN
    Disaster Med Public Health Prep; 2024 Apr; 18():e66. PubMed ID: 38618867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
    Hayer J; Urlaub E
    Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Wittmann I; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Polivka L; Pálosi M; Szlávik J; Rokszin G; Müller C; Szekanecz Z; Kásler M
    Front Immunol; 2022; 13():919408. PubMed ID: 35935993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Antibody Levels Produced by Pfizer, AstraZeneca, and Sinopharm Vaccination in COVID-19 Patients in Erbil City-Iraq.
    Majed SO
    Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):103-112. PubMed ID: 37300682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
    Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
    Front Immunol; 2022; 13():917905. PubMed ID: 35799790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
    Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers].
    Çiçek K; Özkaya Y; Eser E; Buran ZC; Öztürk Arıkan ZÖ; Akçalı S; Erbay Dündar P; Cengiz Özyurt B; Şenol Akar Ş; Özer D; Karadağ Yalçın F
    Mikrobiyol Bul; 2023 Apr; 57(2):238-251. PubMed ID: 37067208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers.
    Rasheed WS; Sarkees AN
    Medicine (Baltimore); 2023 Oct; 102(40):e35444. PubMed ID: 37800839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components.
    Busà R; Sorrentino MC; Russelli G; Amico G; Miceli V; Miele M; Di Bella M; Timoneri F; Gallo A; Zito G; Di Carlo D; Conaldi PG; Bulati M
    Front Immunol; 2022; 13():856657. PubMed ID: 35401503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
    Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
    Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers.
    Alqassieh R; Suleiman A; Abu-Halaweh S; Santarisi A; Shatnawi O; Shdaifat L; Tarifi A; Al-Tamimi M; Al-Shudifat AE; Alsmadi H; Al Sharqawi A; Alnawaiseh H; Anasweh Y; Domaidah FA; Jaber HA; Al-Zarir MR; Bsisu I
    Vaccines (Basel); 2021 Oct; 9(11):. PubMed ID: 34835153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses - fall 2021, Wisconsin.
    DeJonge PM; Lambrou AS; Segaloff HE; Bateman A; Sterkel A; Griggs C; Baggott J; Kelly P; Thornburg N; Epperson M; Desamu-Thorpe R; Abedi G; Hsu CH; Nakayama JY; Ruffin J; Turner-Harper D; Matanock A; Almendares O; Whaley M; Chakrabarti A; DeGruy K; Daly M; Westergaard R; Tate JE; Kirking HL
    BMC Infect Dis; 2023 Jun; 23(1):374. PubMed ID: 37277736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients.
    Saiag E; Grupper A; Avivi I; Elkayam O; Ram R; Herishanu Y; Cohen Y; Perry C; Furer V; Katchman H; Rabinowich L; Ben-Yehoyada M; Halperin T; Baruch R; Goldshmidt H; Hagin D; Ben-Ami R; Sprecher E; Bomze D
    Clin Microbiol Infect; 2022 May; 28(5):735.e5-735.e8. PubMed ID: 35183747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan.
    Jaber HM; Ebdah S; Al Haj Mahmoud SA; Abu-Qatouseh L; Jaber YH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2333104. PubMed ID: 38584118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.